These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Leucine-rich repeat kinase 2 expression leads to aggresome formation that is not associated with alpha-synuclein inclusions. Waxman EA; Covy JP; Bukh I; Li X; Dawson TM; Giasson BI J Neuropathol Exp Neurol; 2009 Jul; 68(7):785-96. PubMed ID: 19535993 [TBL] [Abstract][Full Text] [Related]
5. LRRK2 interactions with α-synuclein in Parkinson's disease brains and in cell models. Guerreiro PS; Huang Y; Gysbers A; Cheng D; Gai WP; Outeiro TF; Halliday GM J Mol Med (Berl); 2013 Apr; 91(4):513-22. PubMed ID: 23183827 [TBL] [Abstract][Full Text] [Related]
6. Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2. Daher JP; Pletnikova O; Biskup S; Musso A; Gellhaar S; Galter D; Troncoso JC; Lee MK; Dawson TM; Dawson VL; Moore DJ Hum Mol Genet; 2012 Jun; 21(11):2420-31. PubMed ID: 22357653 [TBL] [Abstract][Full Text] [Related]
7. Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. Higashi S; Biskup S; West AB; Trinkaus D; Dawson VL; Faull RL; Waldvogel HJ; Arai H; Dawson TM; Moore DJ; Emson PC Brain Res; 2007 Jun; 1155():208-19. PubMed ID: 17512502 [TBL] [Abstract][Full Text] [Related]
8. Brain and Cerebrospinal Fluid α-Synuclein Real-Time Quaking-Induced Conversion Identifies Lewy Body Pathology in LRRK2-PD. Garrido A; Fairfoul G; Tolosa E; Marti MJ; Ezquerra M; Green AJE Mov Disord; 2023 Feb; 38(2):333-338. PubMed ID: 36471633 [TBL] [Abstract][Full Text] [Related]
9. Autosomal dominant Parkinson's disease and the route to new therapies. Morris HR Expert Rev Neurother; 2007 Jun; 7(6):649-56. PubMed ID: 17563248 [TBL] [Abstract][Full Text] [Related]
10. α-Synuclein mRNA and soluble α-synuclein protein levels in post-mortem brain from patients with Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease. Quinn JG; Coulson DT; Brockbank S; Beyer N; Ravid R; Hellemans J; Irvine GB; Johnston JA Brain Res; 2012 Jun; 1459():71-80. PubMed ID: 22560502 [TBL] [Abstract][Full Text] [Related]
11. Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases. Mamais A; Raja M; Manzoni C; Dihanich S; Lees A; Moore D; Lewis PA; Bandopadhyay R Neurobiol Dis; 2013 Oct; 58():183-90. PubMed ID: 23747310 [TBL] [Abstract][Full Text] [Related]
12. A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Melrose HL; Kent CB; Taylor JP; Dachsel JC; Hinkle KM; Lincoln SJ; Mok SS; Culvenor JG; Masters CL; Tyndall GM; Bass DI; Ahmed Z; Andorfer CA; Ross OA; Wszolek ZK; Delldonne A; Dickson DW; Farrer MJ Neuroscience; 2007 Jul; 147(4):1047-58. PubMed ID: 17611037 [TBL] [Abstract][Full Text] [Related]